Effectiveness of LORlatinib as a Real-World, first-line treatment in ALK-positive Advanced Non-Small Cell Lung Cancer Patients in Germany. (LOR-ALK).

ENCePP Code of conduct

N/A

Data sources

• Data sources (types):
  Electronic healthcare records (EHR)

  Non-interventional study

  Patient surveys

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No